Lunit

Lunit Debt/EBITDA

The Total Debt to EBITDA Ratio of Lunit (328130.KQ) as of Oct 16, 2026 is 11.55. In the previous year, Total Debt to EBITDA Ratio was -5.65 — a change of -304.51% (higher).

Debt/EBITDA

11.55

YoY

-304.51%

Last updated:

Total Debt to EBITDA Ratio of Lunit is 2024 11.55 . Total Debt to EBITDA Ratio of Lunit was 2023 -5.65 . It decreases by -304.51% higher compared to the previous year.

The Lunit Debt/EBITDA history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Debt/EBITDA
Date
Debt/EBITDA
Jan 1, 2019
0.00 KRW
Jan 1, 2020
-1.64 KRW
Jan 1, 2021
-0.02 KRW
Jan 1, 2022
12.27 KRW
Jan 1, 2023
-5.65 KRW
Jan 1, 2024
11.55 KRW
The Lunit Debt/EBITDA history
YEARDebt/EBITDAYoY
11.55-304.51%
-5.65-146.00%
12.27-57,230.25%
-0.02-98.69%
-1.64—
0.00—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Lunit Stock analysis

What does Lunit do? Lunit Inc is a South Korean company headquartered in Seoul, operating within the Health Care sector. The company has 293 employees and went public on July 21, 2022, with its ticker listed as 328130.KQ and ISIN KR7328130000. Lunit provides software solutions for medical diagnostic imaging services, focusing on the development and supply of AI-powered medical software. Its offerings include cancer diagnostic aid solutions, cancer early detection solutions, and cancer risk prediction solutions. The company's technology leverages artificial intelligence to enhance diagnostic capabilities in healthcare settings. Lunit's website is www.lunit.io, where further information about its services and solutions can be accessed. The company operates in the Health Care industry, specifically targeting medical imaging and AI-driven diagnostic tools. As of the latest available data, Lunit is engaged in the development and commercialization of AI-based medical software, aiming to improve the accuracy and efficiency of cancer-related diagnostics. The firm's IPO date marks its transition to a publicly traded company, reflecting its growth and market position in the healthcare technology space. Lunit's focus on AI applications in medical imaging positions it as a key player in the digital health sector, particularly within the Korean market and beyond. The company's solutions are designed to support healthcare professionals in making more informed diagnostic decisions, potentially reducing the time and resources required for cancer detection and treatment planning. Lunit is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Lunit stock

Total Debt to EBITDA Ratio of Lunit is 11.55 in 2024.

Total Debt to EBITDA Ratio of Lunit changed from -5.65 to 11.55, representing a -304.51% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Total Debt to EBITDA Ratio Lunit since 2006 – with annual values, charts, and detailed analysis.

Debt/EBITDA measures total debt relative to earnings before interest, taxes, depreciation, and amortization. It indicates the years needed to repay all debt from EBITDA.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Total Debt to EBITDA Ratio's Lunit with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Leverage — Lunit

All Key Metrics — Lunit